Check out the latest features and columns!

Pharmaceutical Executive November 2021

These five brands prove that pharma marketers can pull it together with compelling stories,  and meaningful patient impact, even during  a pandemic.

New Heights

November's Executive Profile features Moderna Chief Medical Officer Paul Burton

Crafting Cures

How can clinical trials be designed to best study therapies for treating long COVID?

Uncovering Long-Term COVID in Drug Development

Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID.

2021 Pharm Exec 50

Read the profiles of 13 diverse leaders vital to the future of the biopharma industry.

Pharm Exec's 2021 Emerging Pharma Leaders

With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.

2021 in Focus: Pharm Exec’s Annual Industry Outlook

Articles

This partnership enhances Key Opinion Leader (KOL) mapping and profiling capabilities for MSL solutions within the Medical Affairs Specialist Area of Ashfield Engage. 

Ashfield Engage Announces New Technology Partnership with PeakData

Jill Wechsler is Pharm Exec's Washington Corespondent

Leading legislators have launched the campaign to enact a second version of the 21st Century Cures Act.

New Cures 2.0 Legislation Advances Biomedical Research & Care

An extension of an article in the November issue of Pharmaceutical Executive titled “Turning the Corner: A New Era of Pharma Sales Comes into View,” this Q&A session further addresses the pandemic-enhanced benefits of virtual events, both as incredible sources of information and education as well as a new digital tool for the evolving sales representative.

Virtual Events: Q&A with Jenna Sherlock of Veeva and Neel Edeling of Lundbeck

Dr. John Price is an executive physician with 25+ years deep experience working across regulatory affairs and pharmacovigilance worldwide. He has held senior roles at the UK MHRA, as well as Pfizer, J&J, Alexion Pharmaceuticals, and worked in academia. John is an advisor to 

, a provider of risk management and compliance services to the life sciences sector – including market consultancy, global regulatory affairs strategy and implementation, complete PV solutions, clinical drug safety, and quality and compliance auditing systems.

According to new research, quality has overtaken cost as a priority in plans for automating adverse event reporting. John Price reveals the drivers and barriers to change.

Quality More Important than Cost: Building the Business Case for PV Automation

Gareth Shaw is President, UK & Europe of Doceree, the first global network of physician-only platforms for programmatic messaging. Gareth has an extensive background in the sales categories across the digital media and advertising technology sectors. Throughout his career, Gareth has a history of building high-performance teams and implementing strategic plans to facilitate the growth of his organizations. 

Healthcare professionals (HCPs) shouldn’t miss out on critical information while their focus is on their patients, which is why messages on professional platforms are an essential resource to improve a patient’s health results, writes Gareth Shaw.

Using Identity Resolution Technology to Dispense Hyper-Relevant Information to HCPs

Brian Flatley is VP Consulting Services at 

How can pharma create solutions that are effective, can provide long-term value, and will actually be adopted by HCPs and patients?

Why Pharma Should Develop a Core Digital Offering

 is Managing Director of Iperion - a Deloitte business, where he leads a team of regulatory/IDMP experts active in various projects to deliver value to both pharmaceutical companies as well as regulators. In addition to having more than two decades’ industry and consultancy experience, Frits is regarded internationally as a subject matter expert on IDMP and he proactively shares his rich knowledge and experience wherever he can. Iperion, now part of Deloitte, is a globally-operating life sciences consultancy firm which is paving the way to digital healthcare, by supporting standardization and ensuring the right technology, systems and processes are in place to enable insightful business decision-making and innovation.

The Identification of Medicinal Products (IDMP) software industry has talked up the broader potential of data-driven processes. Pharma companies and their software providers have an important role to play in realizing these processes. Frits Stulp discusses the foundations that need to be laid for lasting transformation of pharma information access in the real world.

Why Pharma’s Approach to IDMP Today Will Matter to Patients & Physicians Tomorrow

The White House nominates Robert Califf to once again take the reins of FDA, but acting commissioner Janet Woodcock will remain in place during the Senate confirmation process.

Califf Named to Head FDA

The Democratic proposal to authorize price negotiations on costly medicines covered by Medicare and to penalize firms that raise prices faster than inflation has drawn opposition pharma and biotech companies. More surprisingly, generic companies also are objecting to the changes on the table.

Generics Makers Also Fight Price Controls

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mjhlifesciences.com

Podcasts

Jeff Stoll, US Life Sciences Strategy Leader at KPM, talks about some of the highlights from KPMG’s recent Global Pharma CEO Outlook report.